Supernus Pharmaceuticals (SUPN) Cost of Revenue (2013 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Cost of Revenue of $33.7 million for Q2 2026, up 100.09% year-over-year from $16.8 million in Q2 2025, and up 46.34% on a QoQ basis from $23.0 million in Q4 2025.
Supernus Pharmaceuticals (SUPN) Cost of Revenue (2013 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Cost of Revenue for 14 years, with the latest figure at $33.7 million in Q2 2026.
- Cost of Revenue for Q2 2026 came in at $33.7 million, up 100.09% year-over-year; the trailing twelve-month figure through Jun 2026 was $92.5 million (up 21.24% YoY), and the FY2025 annual result was $74.6 million, down 4.29% from the prior year.
- Cost of Revenue advanced to $33.7 million in Q2 2026, from $23.0 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $33.7 million in Q2 2026 and troughed at $15.8 million in Q1 2025.
- A 5-year average of $21.0 million and a median of $19.6 million in 2023 frame the typical range for Cost of Revenue.
- The widest annual swing landed in 2024, when Cost of Revenue sank 30.48%; it then soared 100.09% in 2026.
- A 5-year view of Cost of Revenue shows it stood at $23.0 million in 2022, then decreased by 14.49% to $19.6 million in 2023, then surged by 32.97% to $26.1 million in 2024, then retreated by 11.84% to $23.0 million in 2025, then soared by 46.34% to $33.7 million in 2026.
- Per Business Quant data, the three most recent Cost of Revenue figures were $33.7 million in Q2 2026, $23.0 million in Q4 2025, and $19.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.77 Bn | 2.40 Bn | 185.39 Mn | 33.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.67 Mn |
| Jun 30, 2026 | 33.67 Mn |
| Dec 31, 2025 | 23.01 Mn |
| Dec 31, 2025 | 23.01 Mn |
| Sep 30, 2025 | 18.97 Mn |
| Sep 30, 2025 | 18.97 Mn |
| Jun 30, 2025 | 16.83 Mn |
| Jun 30, 2025 | 16.83 Mn |
| Mar 31, 2025 | 15.76 Mn |
| Mar 31, 2025 | 15.76 Mn |
| Dec 31, 2024 | 26.10 Mn |
| Dec 31, 2024 | 26.10 Mn |
| Sep 30, 2024 | 17.58 Mn |
| Sep 30, 2024 | 17.58 Mn |
| Jun 30, 2024 | 17.92 Mn |
| Jun 30, 2024 | 17.92 Mn |
| Mar 31, 2024 | 16.31 Mn |
| Mar 31, 2024 | 16.31 Mn |
| Dec 31, 2023 | 19.63 Mn |
| Dec 31, 2023 | 19.63 Mn |